PCA
ALNY icon

Pallas Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Pallas Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$663K Sell
2,203
-9
-0.4% -$2.71K 0.02% 482
2026
Q1 		$732K Sell
2,212
-1,897
-46% -$646K 0.03% 404
2025
Q4 		$1.63M Sell
4,109
-316
-7% -$140K 0.05% 255
2025
Q3 		$2.02M Buy
4,425
+1,855
+72% +$755K 0.07% 207
2025
Q2 		$838K Sell
2,570
-4,065
-61% -$1.12M 0.03% 368
2025
Q1 		$1.79M Buy
6,635
+3,227
+95% +$829K 0.07% 198
2024
Q4 		$802K Buy
3,408
+87
+3% +$22.9K 0.03% 280
2024
Q3 		$975K Buy
3,321
+1,269
+62% +$330K 0.04% 228
2024
Q2 		$486K Buy
+2,052
New +$324K 0.02% 312

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pallas Capital Advisors's ALNY Position: Q2 2026 in Review

Pallas Capital Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.41% in Q2 2026, selling an estimated $2.71K and leaving 2,203 shares worth $663K. The position accounts for 0.02% of the portfolio, ranked #482.

Pallas Capital Advisors first reported a position in ALNY in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.02M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Pallas Capital Advisors held 2,203 shares of Alnylam Pharmaceuticals worth $663K as of Q2 2026.
  • Pallas Capital Advisors sold 9 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $2.71K.
  • Alnylam Pharmaceuticals made up 0.02% of Pallas Capital Advisors's portfolio in Q2 2026, its #482 holding.
  • Pallas Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Pallas Capital Advisors's Alnylam Pharmaceuticals position peaked at $2.02M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.